Actos pioglitazone: Postmarketing study data

Researchers at the University of East Anglia and Johns Hopkins University School of Medicine reported data from a meta-analysis of 16 observational studies in 810,000 patients showing that use of Avandia rosiglitazone significantly increased the risk of MI (OR=1.16, 95% CI: 1.07, 1.24), CHF (OR=1.22, 95% CI: 1.14, 1.31) and overall mortality (OR=1.14, 95% CI: 1.09, 1.2) vs. Actos pioglitazone (p<0.001 for all). The researchers also estimated that for every 100,000 patients treated with Avandia rather than Actos, there are 170, 649 and 431 additional heart attacks, cases of heart failure and deaths, respectively. Data were published in the British Medical Journal. ...